ArticleBritish journal of cancer2009
HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 115 citations in OpenAlex.
- Review
- Toward a cell-type-specific lung HOX code.Frontiers in cell and developmental biology · 2026Article
- Using the Conserved Hexapeptide in HOX Proteins as an Antagonist of HOX/PBX Interactions.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A multi-level investigation of the genetic relationship between gastroesophageal reflux disease and lung cancer.Translational lung cancer research · 2024Article
- Peptides as multifunctional players in cancer therapy.Experimental & molecular medicine · 2023Review
- Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells.Science advances · 2023Article
- Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer.International journal of cancer · 2022Review
- A Computer-Based Methodology to Design Non-Standard Peptides Potentially Able to Prevent HOX-PBX1-Associated Cancer Diseases.International journal of molecular sciences · 2021Article
- Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway.Oncogene · 2021Article
- Effects of MicroRNA-195-5p on Biological Behaviors and Radiosensitivity of Lung Adenocarcinoma Cells via Targeting HOXA10.Oxidative medicine and cellular longevity · 2021Article
- Identification of HOXD10 as a Marker of Poor Prognosis in Glioblastoma Multiforme.OncoTargets and therapy · 2021Article
- HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair.Thoracic cancer · 2020Article
- Mapping the native interaction surfaces of PREP1 with PBX1 by cross-linking mass-spectrometry and mutagenesis.Scientific reports · 2020Article
- Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.Cancers · 2020Article
- A Novel Role for the Tumor Suppressor GeneCancers · 2020Article
- Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.Oncogene · 2020Review
- Posttranscriptional Gene Regulatory Networks in Chronic Airway Inflammatory Diseases:Frontiers in immunology · 2020Article
- HOXA5 Expression Is Elevated in Breast Cancer and Is Transcriptionally Regulated by Estradiol.Frontiers in genetics · 2020Article
- Oncogenic and tumor suppressor function of MEIS and associated factors.Turkish journal of biology = Turk biyoloji dergisi · 2020Article
- PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma.BioMed research international · 2020Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The HOX genes are a family of homeodomain-containing transcription factors that determine the identity of cells and tissues during embryonic development. They are also known to behave as oncogenes in some haematological malignancies. In this study, we show that the expression of many of the HOX genes is highly elevated in primary non-small-cell lung cancers (NSCLCs) and in the derived cell lines A549 and H23. Furthermore, blocking the activity of HOX proteins by interfering with their binding to the PBX co-factor causes these cells to undergo apoptosis in vitro and reduces the growth of A549 tumours in vivo. These findings suggest that the interaction between HOX and PBX proteins is a potential therapeutic target in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.